指南与共识泌尿男性生殖肿瘤

肾细胞癌新辅助治疗病理缓解评估:系统综述与取样报告标准指南

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
指南 / 共识 · Lancet Oncol · 2025-01-01

该系统综述纳入119篇肾细胞癌新辅助治疗相关文献,发现仅5篇(4%)描述了病理缓解评估方法,8篇(7%)采用定量评估。国际新辅助肾癌联盟据此制定指南,推荐肾切除标本采用标准化基线取样、以10%间隔量化残余活肿瘤并记录最大线性范围,病理评估需附临床治疗信息。

要点

  • 现有肾细胞癌新辅助治疗病理缓解报告缺乏共识,定量评估极少。
  • 推荐肾切除标本标准化取样,以10%间隔量化残余活肿瘤并记录最大线性范围。
  • 病理评估应附新辅助治疗等临床信息,指南暂适用于临床试验或研究场景。

核心结论

  • 肾细胞癌新辅助治疗病理缓解报告缺乏统一标准,国际新辅助肾癌联盟提出标准化取样与报告指南。

研究设计与样本

  • 系统综述检索PubMed与Web of Science数据库,纳入119篇报告肾细胞癌术前治疗反应的文献。
  • 指南经2024年10月荷兰癌症研究所国际研讨会 review 及专家讨论制定。

主要发现

  • 仅5篇(4%)研究包含病理缓解评估方法细节。
  • 55篇(46%)研究使用残余肿瘤定性描述,仅8篇(7%)采用定量评估。

关键数值与推荐

  • 肾切除标本应采用标准化基线取样,并考虑更广泛取样。
  • 显微镜评估应以10%间隔量化残余活肿瘤并记录最大线性范围。
  • 病理评估应附新辅助治疗等临床信息。

临床怎么用

  • 该标准化方法初步用于临床试验或研究场景,帮助评估病理缓解程度与生存结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to pre-surgical therapy in renal cell carcinoma. 119 eligible papers were identified. Only five (4%) studies included details of how pathological response had been assessed. Qualitative statements on residual tumour were common (55 [46%] studies), but only eight (7%) studies used a quantitative assessment of pathological response. Guidelines for tissue preparation and pathological response reporting were reviewed at an international workshop held at the Netherlands Cancer Institute in October, 2024, and further developed through expert discussions. To assess neoadjuvant pathological response, nephrectomy specimens should be sampled with the use of a standardised baseline approach with consideration for more extensive sampling. Microscopic assessment should quantify the residual viable tumour in 10% intervals and greatest linear extent. Clinical details, including the neoadjuvant therapy received, should accompany the pathological assessment. In this systematic review, we describe a standardised method for assessment and reporting pathological response, initially intended for use in clinical trials or research settings. These guidelines will help investigators to assess whether the degree of pathological response is linked to survival outcomes and will inform future standard reporting practices.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Blackmur JP, van der Mijn JCK, Warren AY, et al. Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium. Lancet Oncol. 2025. PMID: 41038202. doi:10.1016/S1470-2045(25)00345-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。